Skip to content

A Study to Investigate the Effect of SFF on Glucose and Insulin Responses

Postprandial Glucose, and Insulin Response of Sugars From Fiber: An Acute, Double Blind, Randomized Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05587426
Enrollment
20
Registered
2022-10-20
Start date
2022-06-03
Completion date
2022-07-29
Last updated
2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Glycemic Response

Brief summary

This goal of this clinical study is to investigate the postprandial glycemic and insulinemic response in healthy adults after the consumption of: 1. Sugars from Fiber in comparison with dextrose 2. Sugars from Fiber incorporated into chocolate chips in comparison with regular chocolate chips

Interventions

DIETARY_SUPPLEMENTSFF

Ingestion of 20g of SFF after 10-14 hours of fasting

DIETARY_SUPPLEMENTGlucose

Ingestion of 20g of glucose after 10-14 hours of fasting

DIETARY_SUPPLEMENTSFF chocolate chips

Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting

DIETARY_SUPPLEMENTRegular chocolate chips

Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting

Sponsors

Cambridge Glycoscience
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Individuals, 20-65 years of age, inclusive. 2. Body mass index (BMI) between 19 and 35 kg/m², inclusive, at screening. 3. Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial. 4. Willing to maintain current dietary supplement and non-exclusionary medication use throughout the trial. 5. Willing to avoid the consumption of alcohol, unusual food intake, and unusual physical activity 24h prior to each study visit. Failure to follow will result in rescheduled visit. 6. Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected. health information to the study investigator.

Exclusion criteria

1. Failure to meet any one of the inclusion criteria. 2. Known history of gastrointestinal disease (e.g., diverticulitis, Crohns disease, coeliac disease etc.), bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, or biliary diseases, or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results. 3. Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results. 4. Major trauma or surgical event within 3 months of screening. 5. Unwillingness or inability to comply with the experimental procedures and to follow INQUIS safety guidelines. 6. Known intolerance, sensitivity or allergy to test foods. 7. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.). 8. History of cancer in the prior two years, except for non-melanoma skin cancer. 9. Exposure to any non-registered drug product within 30 d prior to screening. 10. Self-reported pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Plasma glucose iAUC (T0 - T120min) after test mealsThrough intervention periods of two hoursCompare the postprandial glucose incremental area under the curve after consumption of: SFF compared to glucose or SFF chocolate chips compared to regular chocolate chips

Secondary

MeasureTime frameDescription
Plasma glucose at each time point after test mealsThrough intervention periods of two hoursCompare the postprandial glucose levels at each time point after consumption of: SFF compared to glucose or SFF chocolate chips compared to regular chocolate chips
Serum insulin iAUC (T0 - T120min) and each time point after test mealsThrough intervention periods of two hoursCompare the postprandial insulin levels at each time and incremental area under the curve after consumption of: SFF compared to glucose or SFF chocolate chips compared to regular chocolate chips

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026